Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Incretin-Based Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Incretin-Based Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Glucagon-like peptide-1 receptor (GLP-1) agonists
      • 1.3.3 Dipeptidyl Peptidase-4 (DPP-4) inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global Incretin-Based Drugs Market Share by Application (2019-2025)
      • 1.4.2 Oral Drugs
      • 1.4.3 Injectable Drugs
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Incretin-Based Drugs Market Size
      • 2.1.1 Global Incretin-Based Drugs Revenue 2014-2025
      • 2.1.2 Global Incretin-Based Drugs Sales 2014-2025
    • 2.2 Incretin-Based Drugs Growth Rate by Regions
      • 2.2.1 Global Incretin-Based Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Incretin-Based Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Incretin-Based Drugs Sales by Manufacturers
      • 3.1.1 Incretin-Based Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Incretin-Based Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Incretin-Based Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Incretin-Based Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Incretin-Based Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Incretin-Based Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Incretin-Based Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Incretin-Based Drugs Market
    • 3.6 Key Manufacturers Incretin-Based Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Glucagon-like peptide-1 receptor (GLP-1) agonists Sales and Revenue (2014-2019)
      • 4.1.2 Dipeptidyl Peptidase-4 (DPP-4) inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global Incretin-Based Drugs Sales Market Share by Type
    • 4.3 Global Incretin-Based Drugs Revenue Market Share by Type
    • 4.4 Incretin-Based Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Incretin-Based Drugs Sales by Application

    6 United States

    • 6.1 United States Incretin-Based Drugs Breakdown Data by Company
    • 6.2 United States Incretin-Based Drugs Breakdown Data by Type
    • 6.3 United States Incretin-Based Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Incretin-Based Drugs Breakdown Data by Company
    • 7.2 European Union Incretin-Based Drugs Breakdown Data by Type
    • 7.3 European Union Incretin-Based Drugs Breakdown Data by Application

    8 China

    • 8.1 China Incretin-Based Drugs Breakdown Data by Company
    • 8.2 China Incretin-Based Drugs Breakdown Data by Type
    • 8.3 China Incretin-Based Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Incretin-Based Drugs Breakdown Data by Company
    • 9.2 Rest of World Incretin-Based Drugs Breakdown Data by Type
    • 9.3 Rest of World Incretin-Based Drugs Breakdown Data by Application
    • 9.4 Rest of World Incretin-Based Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Incretin-Based Drugs Sales by Countries
      • 9.4.2 Rest of World Incretin-Based Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 GlaxoSmithKline
      • 10.1.1 GlaxoSmithKline Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.1.4 Incretin-Based Drugs Product Introduction
      • 10.1.5 GlaxoSmithKline Recent Development
    • 10.2 Johnson & Johnson
      • 10.2.1 Johnson & Johnson Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.2.4 Incretin-Based Drugs Product Introduction
      • 10.2.5 Johnson & Johnson Recent Development
    • 10.3 Merck & Co
      • 10.3.1 Merck & Co Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.3.4 Incretin-Based Drugs Product Introduction
      • 10.3.5 Merck & Co Recent Development
    • 10.4 AstraZeneca
      • 10.4.1 AstraZeneca Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.4.4 Incretin-Based Drugs Product Introduction
      • 10.4.5 AstraZeneca Recent Development
    • 10.5 Novartis
      • 10.5.1 Novartis Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.5.4 Incretin-Based Drugs Product Introduction
      • 10.5.5 Novartis Recent Development
    • 10.6 Eli Lilly and Company
      • 10.6.1 Eli Lilly and Company Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.6.4 Incretin-Based Drugs Product Introduction
      • 10.6.5 Eli Lilly and Company Recent Development
    • 10.7 Boehringer Ingelheim
      • 10.7.1 Boehringer Ingelheim Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.7.4 Incretin-Based Drugs Product Introduction
      • 10.7.5 Boehringer Ingelheim Recent Development
    • 10.8 Takeda Pharmaceutical Company
      • 10.8.1 Takeda Pharmaceutical Company Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.8.4 Incretin-Based Drugs Product Introduction
      • 10.8.5 Takeda Pharmaceutical Company Recent Development
    • 10.9 Sanofi
      • 10.9.1 Sanofi Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Incretin-Based Drugs
      • 10.9.4 Incretin-Based Drugs Product Introduction
      • 10.9.5 Sanofi Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Incretin-Based Drugs Sales Channels
      • 11.2.2 Incretin-Based Drugs Distributors
    • 11.3 Incretin-Based Drugs Customers

    12 Market Forecast

    • 12.1 Global Incretin-Based Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Incretin-Based Drugs Sales Forecast by Type
    • 12.3 Global Incretin-Based Drugs Sales Forecast by Application
    • 12.4 Incretin-Based Drugs Forecast by Regions
      • 12.4.1 Global Incretin-Based Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Incretin-Based Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Incretins are gut derived hormones, released after the ingestion of food. Incretins are classified into glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both the molecules are inactivated by enzyme Dipeptidyl Peptidase-4 (DPP-4).
      Oral traditional anti-diabetic drugs, often fail to maintain the desired normal level of glucose, especially in the postprandial condition.
      This has resulted in a strong need for better therapeutics such as incretin based drugs.
      Incretin not only increases the secretion of insulin by acting on pancreatic beta cells, but also inhibits the release of glucagon by acting on the pancreatic alpha cells.
      In 2019, the market size of Incretin-Based Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Incretin-Based Drugs.

      This report studies the global market size of Incretin-Based Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Incretin-Based Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      GlaxoSmithKline
      Johnson & Johnson
      Merck & Co
      AstraZeneca
      Novartis
      Eli Lilly and Company
      Boehringer Ingelheim
      Takeda Pharmaceutical Company
      Sanofi

      Market Segment by Product Type
      Glucagon-like peptide-1 receptor (GLP-1) agonists
      Dipeptidyl Peptidase-4 (DPP-4) inhibitors

      Market Segment by Application
      Oral Drugs
      Injectable Drugs

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Incretin-Based Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Incretin-Based Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Incretin-Based Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now